title: Aerosolized human extracellular superoxide dismutase prevents hyperoxia-induced lung injury.
abstract: An important issue in critical care medicine is the identification of ways to protect the lungs from oxygen toxicity and reduce systemic oxidative stress in conditions requiring mechanical ventilation and high levels of oxygen. One way to prevent oxygen toxicity is to augment antioxidant enzyme activity in the respiratory system. The current study investigated the ability of aerosolized extracellular superoxide dismutase (EC-SOD) to protect the lungs from hyperoxic injury. Recombinant human EC-SOD (rhEC-SOD) was produced from a synthetic cassette constructed in the methylotrophic yeast Pichia pastoris. Female CD-1 mice were exposed in hyperoxia (FiO2>95%) to induce lung injury. The therapeutic effects of EC-SOD and copper-zinc SOD (CuZn-SOD) via an aerosol delivery system for lung injury and systemic oxidative stress at 24, 48, 72 and 96 h of hyperoxia were measured by bronchoalveolar lavage, wet/dry ratio, lung histology, and 8-oxo-2'-deoxyguanosine (8-oxo-dG) in lung and liver tissues. After exposure to hyperoxia, the wet/dry weight ratio remained stable before day 2 but increased significantly after day 3. The levels of oxidative biomarker 8-oxo-dG in the lung and liver were significantly decreased on day 2 (P<0.01) but the marker in the liver increased abruptly after day 3 of hyperoxia when the mortality increased. Treatment with aerosolized rhEC-SOD increased the survival rate at day 3 under hyperoxia to 95.8%, which was significantly higher than that of the control group (57.1%), albumin treated group (33.3%), and CuZn-SOD treated group (75%). The protective effects of EC-SOD against hyperoxia were further confirmed by reduced lung edema and systemic oxidative stress. Aerosolized EC-SOD protected mice against oxygen toxicity and reduced mortality in a hyperoxic model. The results encourage the use of an aerosol therapy with EC-SOD in intensive care units to reduce oxidative injury in patients with severe hypoxemic respiratory failure, including acute respiratory distress syndrome (ARDS).
authors: Department of Life Sciences, and Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.
authors: Chih-Ching
authors: CC
authors: Yen
authors: Yi-Wen
authors: YW
authors: Lai
authors: Hsiao-Ling
authors: HL
authors: Chen
authors: Cheng-Wei
authors: CW
authors: Lai
authors: Chien-Yu
authors: CY
authors: Lin
authors: Wei
authors: W
authors: Chen
authors: Yu-Ping
authors: YP
authors: Kuan
authors: Wu-Huei
authors: WH
authors: Hsu
authors: Chuan-Mu
authors: CM
authors: Chen
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000280:Administration, Inhalation; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000032:analysis; D005260:Female; D006801:Humans; D018496:Hyperoxia / Q000150:complications / Q000517:prevention & control*; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D055370:Lung Injury / Q000401:mortality / Q000517:prevention & control*; D051379:Mice; D012128:Respiratory Distress Syndrome / Q000517:prevention & control; D013482:Superoxide Dismutase / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D000080242:8-Hydroxy-2'-Deoxyguanosine; D013482:Superoxide Dismutase; D003849:Deoxyguanosine